Alaunos Therapeutics, Inc. (TCRT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 1M 2M 3M Q3 '18: 1.7M Q4 '18: 146K Q4 '20: 0 Q2 '22: 398K Q3 '22: 2.9M Q4 '22: 2.9M Q1 '23: 2.9M Q2 '23: 2.9M Q3 '23: 15K Q4 '23: 5K Q1 '24: 6K Q2 '24: 6K Q3 '24: 6K Q4 '24: 9K Q1 '25: 10K Q2 '25: 6K Q3 '25: 6K Q4 '25: 5K Q1 '26: 3K Q2 '26: 3K Q4 '18 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-105M -70M -35M 0 35M 70M 105M Q3 '21: -89.3M Q4 '21: -77.5M Q1 '22: -65.1M Q2 '22: -51.7M Q3 '22: -37.6M Q4 '22: -35.1M Q1 '23: -35.7M Q2 '23: -34.4M Q3 '23: -34.8M Q4 '23: -34.3M Q1 '24: -26.3M Q2 '24: -19.5M Q3 '24: -12M Q4 '24: -4.8M Q1 '25: -4.2M Q2 '25: -4M Q3 '25: -4.1M Q4 '25: -4.2M Q1 '26: -4.1M Q2 '26: -4.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-105M -70M -35M 0 35M 70M 105M Q3 '21: -89.7M Q4 '21: -78.8M Q1 '22: -67M Q2 '22: -54.2M Q3 '22: -40.4M Q4 '22: -37.7M Q1 '23: -38M Q2 '23: -36.8M Q3 '23: -36.5M Q4 '23: -4.7M Q1 '24: 3.7M Q2 '24: 11.3M Q3 '24: 18.7M Q4 '24: -4.7M Q1 '25: -4.1M Q2 '25: -4M Q3 '25: -4M Q4 '25: -4.2M Q1 '26: -4.1M Q2 '26: -4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q3 '21: -63.4M Q4 '21: -61.5M Q1 '22: -53.9M Q2 '22: -40.7M Q3 '22: -37.2M Q4 '22: -29.2M Q1 '23: -30.8M Q2 '23: -29.7M Q3 '23: -29.9M Q4 '23: -30.1M Q1 '24: -22.7M Q2 '24: -17.4M Q3 '24: -11.8M Q4 '24: -5M Q1 '25: -3.8M Q2 '25: -2.8M Q3 '25: -2.9M Q4 '25: -2.9M Q1 '26: -3.1M Q2 '26: -2.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q1 '20: -41.3M Q2 '20: -50.7M Q3 '20: -57.7M Q4 '20: -66.8M Q1 '21: -72.4M Q2 '21: -78.2M Q3 '21: -70.1M Q4 '21: -64.8M Q1 '22: -56.6M Q2 '22: -41.5M Q3 '22: -37.7M Q4 '22: -29.4M Q1 '23: -31.1M Q2 '23: -30M Q3 '23: -30.2M Q4 '23: -30.3M Q1 '24: -22.8M Q2 '24: -17.4M Q3 '24: -11.8M Q4 '24: -5M Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 80M 160M 240M Q2 '11: 67.2M Q3 '11: 68.1M Q2 '12: 78.5M Q3 '12: 78.7M Q2 '21: 214.4M Q3 '21: 214.5M Q1 '22: 214.9M Q2 '22: 215M Q3 '22: 215.1M Q1 '23: 16M Q2 '23: 1.6M Q3 '23: 1.6M Q1 '24: 1.6M Q2 '24: 1.6M Q3 '24: 1.6M Q1 '25: 1.6M Q2 '25: 1.7M Q3 '25: 2.2M Q1 '26: 1.9M Q2 '26: 2.4M Q3 '11 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18.00 -12.00 -6.00 0.00 6.00 12.00 18.00 Q3 '21: -0.43 Q4 '21: -0.38 Q1 '22: -0.33 Q2 '22: -0.27 Q3 '22: -0.20 Q4 '22: -2.62 Q1 '23: -3.20 Q2 '23: -8.64 Q3 '23: -13.90 Q4 '23: -16.32 Q1 '24: -16.74 Q2 '24: -11.96 Q3 '24: -7.36 Q4 '24: -2.92 Q1 '25: -2.54 Q2 '25: -2.46 Q3 '25: -2.31 Q4 '25: -2.21 Q1 '26: -2.13 Q2 '26: -1.91 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.